Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Trotman

Showing results (101-110 of 148) with videos related to

Pageof 15
Sort By:
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Advances in Therapy|July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three StudiesWei Xu, Shenmiao Yang, Constantine S Tam, et al.
Cancer Epidemiology|September 4, 2022
Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control studyMichael K Odutola, Marina T van Leeuwen, Jennifer Turner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
American Journal of Hematology|May 24, 2022
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responsesBrendan Beaton, Sarah C Sasson, Katherine Rankin, et al.
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Blood Advances|March 14, 2024
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignanciesSara Carrillo de Albornoz, Alisa M Higgins, Dennis Petrie, et al.
Haematologica|March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyAllison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
Frontiers in Nutrition|January 23, 2023
Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control studyMichael K Odutola, Marina T van Leeuwen, Julie K Bassett, et al.
Occupational and Environmental Medicine|September 18, 2023
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control studyMichael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, et al.
Pageof 15

Showing results (101-110 of 148) with videos related to

Sort By:
Pageof 15
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Advances in Therapy|July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three StudiesWei Xu, Shenmiao Yang, Constantine S Tam, et al.
Cancer Epidemiology|September 4, 2022
Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control studyMichael K Odutola, Marina T van Leeuwen, Jennifer Turner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
American Journal of Hematology|May 24, 2022
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responsesBrendan Beaton, Sarah C Sasson, Katherine Rankin, et al.
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Blood Advances|March 14, 2024
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignanciesSara Carrillo de Albornoz, Alisa M Higgins, Dennis Petrie, et al.
Haematologica|March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyAllison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
Frontiers in Nutrition|January 23, 2023
Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control studyMichael K Odutola, Marina T van Leeuwen, Julie K Bassett, et al.
Occupational and Environmental Medicine|September 18, 2023
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control studyMichael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, et al.
Pageof 15